Investigating light therapy's effect on circadian rhythm in ICU patients with heart attacks
The Circadian Rhythm of ICU Patients With Acute Myocardial Infraction and the Effect of Dynamic Light Therapy : A Preliminary Study
This study is testing if light therapy can help improve the sleep patterns and recovery of ICU patients who have had heart attacks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 35 Years to 85 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Taoyuan city) |
| Trial ID | NCT04953767 on ClinicalTrials.gov |
What this trial studies
This study monitors the circadian rhythm changes in ICU patients suffering from acute myocardial infarction and evaluates the impact of light therapy. It involves 70 patients aged 35-85 who are randomly assigned to receive either blue light therapy or placebo white light therapy daily. The researchers will use both subjective and objective measurements, including actigraphy, heart rate variation analysis, and melatonin levels, to assess the effects of the therapy. Delirium severity will also be evaluated using established scales, with follow-up until discharge to determine prognosis.
Who should consider this trial
Good fit: Ideal candidates are ICU patients aged 35-85 diagnosed with acute myocardial infarction of Killip severity I-III.
Not a fit: Patients with severe mental disorders, neurological diseases, or those using sedative hypnotic drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of circadian rhythm disturbances and reduce delirium in ICU patients with acute myocardial infarction.
How similar studies have performed: Other studies have shown promising results with light therapy in managing circadian rhythm disruptions, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis for admission is acute myocardial infarction with severity between Killip I-III. * Age is between 35-85. * Participants who are willing to participate in the study and sign the informed consent. Exclusion Criteria: * Using sedative hypnotic drugs. * Blindness or severe cataract. * Neurological diseases such as epilepsy, brain injury, or stroke. * Severe mental disorder such as major depressive disorder, bipolar disorder, schizophrenia, intellectual disability or substance use disorders. * Unable to communicate. * Participants who are unwilling to participate in the study or refuse to sign the informed consent. * Participants who are not suitable to include in this study, evaluate by PI or Co-PI.
Where this trial is running
Taoyuan city
- Wei-Chih Chin — Taoyuan city, Taiwan (Recruiting)
Study contacts
- Principal investigator: Wei-Chih Chin — Chang Gung Medical Foundation
- Study coordinator: Wei-Chih Chin
- Email: auaug0327@cgmh.org.tw
- Phone: +886 3 3281200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.